Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
Date:5/23/2011

SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

"We are pleased to present data from the long-term follow-up portion of the CUPID trial with MYDICAR demonstrating reduced hospitalizations and other cardiovascular events at 18 months after treatment," said Krisztina Zsebo, Ph.D., CEO and President of Celladon, who presented the study's long-term follow-up results during the American Society of Cell and Gene Therapy 2011.

The study of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, after 12 months of receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003), of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure

Additionally, the 18-month CUPID data from long-term follow-up demonstrate a durable benefit in preventing major cardiovascular events.

The 12 month data presented in 2010 showed that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained stable while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

We believe the efficacy sustained in patients over a 18-mon
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
2. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
3. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
4. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
5. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
6. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
7. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
8. SenSage Named Cerner Corporations Accelerate Partner of the Year
9. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
10. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
11. Omeros Corporation Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... year,s flu season was marked by a particularly aggressive ... experts at Cardinal Health expect the vaccine to be ... The upcoming 2010-2011 flu season marks the first ... Practices (ACIP) has issued a universal vaccination recommendation, encouraging ...
... Biosciences, Inc. announced today the appointment of Merdad V. ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) (Logo: ... pleased to have Merdad as the new CEO of ... is returning to his role as Chairman of the ...
Cached Medicine Technology:Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 2Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 3Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season 43-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer 2
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
(Date:7/31/2015)... ... ... Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award winner ... reduction in New York. Due to its unparalleled level of experience for these ... travel to New York to get their non-surgical skin tightening and body shaping procedures ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Sculpted Contours ... the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the ... January 2014 for treating the outer thighs. The original applicator required a 2 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... Symptoms of sepsis, such as cold hands, severe leg pain ... of bacterial meningitis, parents are being advised. // ... over after meningitis researchers identified new early-warning signs for parents, ... parents have been warned to look out for their child ...
... vegetable rich diet has been found to reduce the risk ... heart attack or strokes, according to a recent diet study. ... Imperial College London studied 4,680 people aged 40-59. They recommend ... a healthy lifestyle for prevention of high blood pressure and ...
... A report published in the January/February issue of General ... journal, says that most children's medicines have the potential ... sugar in them. // ,For example, antihistamine syrups ... low pH levels, which mean that they are high ...
... been found to work under the influence of alcohol ... Institute on Addictions (RIA) of the University of Buffalo. ... agencies were interviewed through telephone to obtain information about ... over the past 12 months. The study sample was ...
... assistance professor of psychology at south-western university and a graduate ... greater effect on the sexual behaviour of female rats. ... among the first to determine the effects of caffeine on ... into the relationship between caffeine and sex. ,The ...
... People worldwide are suffering from cancer. Virgin money life an insurance ... exclusively to cater the needs of cancer patients // . Richard ... cheaper when compared to other insurance cover programme. ... one out of three people suffer from cancer. Institute of cancer ...
Cached Medicine News:Health News:New warning signs for child meningitis 2Health News:Nearly 15% Of U.S. Workers Work Under The Influence Of Alcohol 2Health News:Cancer Cover Insurance “The Big V” Is Launched In U 2
Vaulted shank with guard....
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... head design has been carefully considered with both ... head ensures the optimum viewing angle and the ... laser aligned for perfect focus where it is ... paper. This along with Keeler's wide angle ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: